Status:

COMPLETED

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Lead Sponsor:

Nabi Biopharmaceuticals

Conditions:

Calcinosis

Arteriosclerosis

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron b...

Detailed Description

Cardiovascular disease is the major cause of death and disability in patients with end-stage renal disease on hemodialysis. It has been hypothesized that ingestion of calcium-based phosphate binders r...

Eligibility Criteria

Inclusion

  • Eligible subjects will be male or female patients with end-stage renal disease on maintenance hemodialysis for less than 5 years, with elevated LDL cholesterol
  • Currently treated with oral phosphate binders
  • Coronary artery calcium scores of 30 to 5000 Agatston units measured by electron beam CT scanning
  • Written informed consent
  • Negative serum pregnancy test if appropriate
  • Expect to comply with protocol procedures and schedule

Exclusion

  • Unstable angina pectoris
  • Severe congestive heart failure
  • Severe obstructive pulmonary disease requiring supplemental oxygen
  • Severe liver dysfunction
  • Severe malnutrition
  • Severe hyperparathyroidism
  • Known HIV
  • Active malignancy for which the subject is receiving chemotherapy or radiation
  • Planned renal transplant within the next year
  • Clinical evidence of calciphylaxis or recent history of hypercalcemia
  • History of obstructed bowels
  • Hypersensitivity to any of the components of the study medication
  • History of swallowing disorders
  • Weight \> 300 pounds
  • Any condition which makes patient participation not in the patient's best interest

Key Trial Info

Start Date :

January 1 2005

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

203 Patients enrolled

Trial Details

Trial ID

NCT00211939

Start Date

January 1 2005

End Date

March 1 2007

Last Update

January 8 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Texas Health Sciences Center

San Antonio, Texas, United States, 78229-3900

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients | DecenTrialz